Exact Mass: 369.0857154
Exact Mass Matches: 369.0857154
Found 60 metabolites which its exact mass value is equals to given mass value 369.0857154
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
lansoprazole
C16H14F3N3O2S (369.07587800000005)
A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BC - Proton pump inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29723 - Proton Pump Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS CONFIDENCE standard compound; EAWAG_UCHEM_ID 3137 Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2].
Lansoprazole
C16H14F3N3O2S (369.07587800000005)
Lansoprazole is a proton pump inhibitor similar to omeprazole which prevents the stomach from producing acid. Lansoprazoles plasma elimination half-life is not proportional to the duration of the drugs effects (i.e. gastric acid suppression). The plasma elimination half-life is 1.5 hours or less, and the effects of the drug last for over 24 hours after it has been given for 5 days or more. [HMDB] Lansoprazole is a proton pump inhibitor similar to omeprazole which prevents the stomach from producing acid. Lansoprazoles plasma elimination half-life is not proportional to the duration of the drugs effects (i.e. gastric acid suppression). The plasma elimination half-life is 1.5 hours or less, and the effects of the drug last for over 24 hours after it has been given for 5 days or more. A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BC - Proton pump inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29723 - Proton Pump Inhibitor COVID info from clinicaltrial, clinicaltrials, clinical trial, clinical trials D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors Corona-virus Coronavirus SARS-CoV-2 COVID-19 SARS-CoV COVID19 SARS2 SARS Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2].
Tripamide
C16H20ClN3O3S (369.09138400000006)
Tripamide belongs to the family of Aromatic Monoterpenes. These are monoterpenes containing at least one aromatic ring. D045283 - Natriuretic Agents > D004232 - Diuretics > D049994 - Sodium Potassium Chloride Symporter Inhibitors D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D049990 - Membrane Transport Modulators
6-Hydroxy-R-acenocoumarol
6-Hydroxy-R-acenocoumarol is a metabolite of acenocoumarol. Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist. It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome. (Wikipedia)
7-Hydroxy-R-acenocoumarol
7-Hydroxy-R-acenocoumarol is a metabolite of acenocoumarol. Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist. It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome. (Wikipedia)
8-Hydroxy-R-acenocoumarol
8-Hydroxy-R-acenocoumarol is a metabolite of acenocoumarol. Acenocoumarol is an anticoagulant that functions as a vitamin K antagonist. It is a derivative of coumarin and is marketed under the brand names Sintrom and Sinthrome. (Wikipedia)
Chloro-{methyl-[1-(2-methyl-5,6-dihydro-[1,4]oxathiin-3-yl)-methanoyl]-amino}-benzoic acid, isopropyl ester
C17H20ClNO4S (369.0801510000001)
N-[3-(aminosulfonyl)phenyl]-2-phenoxynicotinamide
C18H15N3O4S (369.07832300000007)
((4,5-dichloro-1H-pyrrol-2-yl)-[2,4-dihydroxy-3-((S)-4-methylhexyl)phenyl]methanone)
(3R)-3-(5,8-dihydroxy-6-methoxy-2-methyl-4-oxo-4H-naphtho[2,3-b]pyran-10-yl)pyrrolidine-2,5-dione|(R)-10-(3-succinimidyl)-TMC-256A1
Lycoramine HBr
C17H24BrNO3 (369.09394540000005)
2H-1-Benzopyran-2-one, 4,8-dihydroxy-3-[(1S)-1-(4-nitrophenyl)-3-oxobutyl]- (Acenocoumarol metaboli
2H-1-Benzopyran-2-one, 4,7-dihydroxy-3-[(1S)-1-(4-nitrophenyl)-3-oxobutyl]- (Acenocoumarol metabolit
Homapin
C17H24BrNO3 (369.09394540000005)
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03B - Belladonna and derivatives, plain > A03BB - Belladonna alkaloids, semisynthetic, quaternary ammonium compounds Homatropine methylbromide (Homatropine methobromide) is muscarinic AChR antagonist, inhibits endothelial and smooth muscle muscarinic receptors of WKY-E and SHR-E with IC50 of 162.5 nM and 170.3 nM, respectively.
Normonal
C16H20ClN3O3S (369.09138400000006)
D045283 - Natriuretic Agents > D004232 - Diuretics > D049994 - Sodium Potassium Chloride Symporter Inhibitors D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents D049990 - Membrane Transport Modulators
10-Methyl-9-phenylacridinium perchlorate
C20H16ClNO4 (369.07678060000006)
Gallium,tris(2,4-pentanedionato-kO,kO)-, (OC-6-11)- (9CI)
5-azido-1,3-dimethyl-6-nitro-8-phenylpyrido[2,3-d]pyrimidine-2,4,7-trione
N-[6-(1H-indazol-5-yl)naphthalen-2-yl]thiophene-2-carboxamide
C22H15N3OS (369.09357800000004)
N-[6-(1H-indazol-4-yl)naphthalen-2-yl]thiophene-3-carboxamide
C22H15N3OS (369.09357800000004)
N-[6-(1H-indazol-5-yl)naphthalen-2-yl]thiophene-3-carboxamide
C22H15N3OS (369.09357800000004)
Thiazolidine, 2-(4-methylphenyl)-3-(1-naphthalenylsulfonyl)- (9CI)
Thiazolidine, 2-(4-methylphenyl)-3-(2-naphthalenylsulfonyl)- (9CI)
Tetraethylenepentamine Pentahydrochloride
C8H28Cl5N5 (369.07872380000003)
3-(Methylsulfonyl)-L-phenylalanine phenylmethyl ester hydrochloride
C17H20ClNO4S (369.0801510000001)
tert-butyl 4-[(4-bromophenyl)methoxy]piperidine-1-carboxylate
C17H24BrNO3 (369.09394540000005)
Dexlansoprazole
C16H14F3N3O2S (369.07587800000005)
A - Alimentary tract and metabolism > A02 - Drugs for acid related disorders > A02B - Drugs for peptic ulcer and gastro-oesophageal reflux disease (gord) > A02BC - Proton pump inhibitors C78276 - Agent Affecting Digestive System or Metabolism > C29701 - Anti-ulcer Agent > C29723 - Proton Pump Inhibitor D005765 - Gastrointestinal Agents > D000897 - Anti-Ulcer Agents D004791 - Enzyme Inhibitors > D054328 - Proton Pump Inhibitors (R)-Lansoprazole is the R enantiomer of Lansoprazole, Lansoprazole (AG 1749) is an orally active proton pump inhibitor which prevents the stomach from producing acid. Lansoprazole (AG 1749) is a potent brain penetrant neutral sphingomyelinase (N-SMase) inhibitor (exosome inhibitor)[1][2].
N-(4-(5-((1H-Benzimidazol-2-ylamino)methyl)-2-thienyl)-1,3-thiazol-2-YL)guanidine
Homatropine Methylbromide
C17H24BrNO3 (369.09394540000005)
A - Alimentary tract and metabolism > A03 - Drugs for functional gastrointestinal disorders > A03B - Belladonna and derivatives, plain > A03BB - Belladonna alkaloids, semisynthetic, quaternary ammonium compounds C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent Homatropine methylbromide (Homatropine methobromide) is muscarinic AChR antagonist, inhibits endothelial and smooth muscle muscarinic receptors of WKY-E and SHR-E with IC50 of 162.5 nM and 170.3 nM, respectively.
Tripamide
C16H20ClN3O3S (369.09138400000006)
D045283 - Natriuretic Agents > D004232 - Diuretics > D049994 - Sodium Potassium Chloride Symporter Inhibitors D002317 - Cardiovascular Agents > D045283 - Natriuretic Agents C78275 - Agent Affecting Blood or Body Fluid > C448 - Diuretic D049990 - Membrane Transport Modulators
2-[(5-butyl-1H-1,2,4-triazol-3-yl)thio]-N-(4-sulfamoylphenyl)acetamide
C14H19N5O3S2 (369.09292639999995)
2-[[1-oxo-2-[[5-(3-pyridinyl)-1H-1,2,4-triazol-3-yl]thio]ethyl]amino]benzoic acid methyl ester
(E)-3-[5-(4-Acetyl-phenyl)-furan-2-yl]-2-(5-methyl-4H-[1,2,4]triazol-3-ylsulfanyl)-acrylic acid
C18H15N3O4S (369.07832300000007)
Isopropyl (3-oxo-1-{[(2-thienylcarbonyl)amino]carbonothioyl}-2-piperazinyl)acetate
N4-(4-Fluorophenyl)-N5-(2-nitrophenyl)-1H-imidazole-4,5-dicarboxamide
C17H12FN5O4 (369.08732840000005)
5-[(2-Chlorophenyl)methylamino]-2-(3,4-dimethoxyphenyl)-4-oxazolecarbonitrile
C19H16ClN3O3 (369.08801360000007)
MMPIP (hydrochloride)
C19H16ClN3O3 (369.08801360000007)
MMPIP hydrochloride is an allosteric metabotropic glutamate receptor 7 (mGluR7) selective antagonist (KB values 24 -30 nM). MMPIP hydrochloride acts as a pharmacological tool for elucidating the roles of mGluR7 on central nervous system functions. MMPIP hydrochloride alleviates pain and normalizes affective and cognitive behavior in neuropathic mice[1][2].